ThePeptide.expert
This information is for research and educational purposes only. This is not medical advice.
← All profiles
Cat 1 — 2026GH axisMetabolicRecovery

Ipamorelin

Growth Hormone Secretagogue (selective)

The most selective GH secretagogue available. Stimulates strong growth hormone release with minimal cortisol or prolactin side effects. Considered the gold standard secretagogue.

Evidence
Human data exists
Routes
injectable
Available since
Developed late 1990s. Clinical and compounding use widespread from approximately 2010 onward.

Mechanism of action

Binds ghrelin receptors (GHS-R1a) selectively on pituitary and hypothalamus. Does not significantly elevate cortisol, ACTH, or prolactin — distinguishing it from older secretagogues like GHRP-2 and GHRP-6 which cause significant cortisol elevation.

Effects in the body

Ipamorelin achieves strong GH pulse stimulation with surgical selectivity. Earlier GHRPs caused cortisol spikes and appetite increase. Ipamorelin achieves comparable GH release without those effects, making it the preferred clinical choice for GH axis optimization.

Pros & cons (from the literature)

Pros
  • No significant cortisol or appetite elevation unlike older secretagogues
  • Strong selective GH pulse stimulation
  • Excellent preclinical safety profile
  • Industry standard — most prescribed secretagogue in clinical settings
  • Synergistic with CJC-1295 for additive GH effect
Cautions
  • Theoretical IGF-1-related cancer risk with long-term use
  • Water retention possible at higher doses
  • Must refrigerate — stability and handling considerations
  • Potential receptor downregulation with continuous use
  • No Phase III approval for healthy adults

Protocol summary (from published research)

200–300 mcg per injection subcutaneous, 1–3 times daily, typically at bedtime. Standard research stack: combine with CJC-1295 (100 mcg) per injection. Typical cycles: 3 months on, 1 month off.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Category 1 as of February 2026. Compoundable with physician prescription from licensed 503A pharmacy. Frequently prescribed alongside CJC-1295 as a standard combination protocol.

Evidence base

Raun et al. 1998 published human pharmacological data. Mechanism well-established. No large randomized controlled trials in healthy adults.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Pro member exclusive

Significant savings on research-grade peptides at a licensed, quality-controlled supplier

Your Pro membership includes an exclusive discount code for 99%+ purity verified research peptides at the best available price, from a licensed supplier we have evaluated for purity standards and compliance. Plus curated guides so you know exactly what to research.

  • • Exclusive discount code included with Pro membership
  • • Curated guide for this specific peptide
  • • Verified 99%+ purity compounds
  • • Removes the guesswork entirely
Upgrade to Pro — $15/month

Cancel anytime · No long-term commitment

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.